$BHC
Bausch Health Companies Inc. · NYSE · Healthcare
- Market cap
- 2.45B
- Volume
- 1.65M
- P/E
- 1.56
- Day range
- 6.53 – 6.71
- 52w range
- 4.33 – 8.00
- Analyst target
- 7.50
AI Summary
Generating a unique summary for BHC…
AI-generated for information only — not investment advice.
Share this ticker
$BHC -2.96% at 6.56 Stanley Druckenmiller and 3 other tracked billionaires hold it. $JNJ $NTRA $LLY https://billionairestrading.com/stocks/BHC
Company summary
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, and internationally. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Institutional ownership
Institutions hold 65.04% · insiders 11.12% · 315 institutions
| Holder | Shares | Value | % held | Reported |
|---|---|---|---|---|
| PAULSON & CO. INC. | 73.26M | $480.56M | 19.58% | 2026-06-30 |
| Goldentree Asset Management LP | 34.67M | $227.41M | 9.27% | 2026-06-30 |
| Royal Bank of Canada | 10.83M | $71.06M | 2.90% | 2026-06-30 |
| Healthcare of Ontario Pension Plan Trust Fund | 8.00M | $52.48M | 2.14% | 2026-06-30 |
| Vanguard Capital Management LLC | 7.47M | $48.97M | 2.00% | 2026-06-30 |
| Goldman Sachs Group Inc | 6.23M | $40.84M | 1.66% | 2026-06-30 |
| MFN Partners Management, LP | 6.00M | $39.36M | 1.60% | 2026-06-30 |
| SG Americas Securities, LLC | 5.54M | $36.31M | 1.48% | 2026-06-30 |
| Acadian Asset Management. LLC | 5.48M | $35.97M | 1.47% | 2026-06-30 |
| Kohlberg Kravis Roberts & Co. L.P. | 5.24M | $34.34M | 1.40% | 2026-06-30 |
Hedge fund & billionaire activity
Insider transactions
| Insider | Role | Transaction | Shares | Date |
|---|---|---|---|---|
| LENAR AIMEE J | Officer | Sale at price 7.03 per share. | 36.8K | 2026-08-19 |
| LEUNG SANDRA | Director | Stock Award(Grant) at price 4.93 per share. | 6.8K | 2026-06-30 |
| PAULSON JOHN A. | Director | Stock Award(Grant) at price 4.93 per share. | 12.7K | 2026-06-30 |
| LEUNG SANDRA | Director | Stock Award(Grant) at price 0.00 per share. | 45.9K | 2026-05-22 |
| KAVANAGH SARAH BALDWIN | Director | Stock Award(Grant) at price 0.00 per share. | 45.9K | 2026-05-22 |
| ROBERTS EIRY WYN | Director | Stock Award(Grant) at price 0.00 per share. | 45.9K | 2026-05-22 |
| GOETTLER MICHAEL | Director | Stock Award(Grant) at price 0.00 per share. | 45.9K | 2026-05-22 |
| POWER ROBERT N | Director | Stock Award(Grant) at price 0.00 per share. | 45.9K | 2026-05-22 |
| GARCIA CHRISTIAN A | Director | Stock Award(Grant) at price 0.00 per share. | 45.9K | 2026-05-22 |
| WECHSLER AMY B | Director | Stock Award(Grant) at price 0.00 per share. | 45.9K | 2026-05-22 |
| PAULSON JOHN A. | Director | Stock Award(Grant) at price 0.00 per share. | 45.9K | 2026-05-22 |
| LEE FRANK DON | Director | Stock Award(Grant) at price 0.00 per share. | 45.9K | 2026-05-22 |
Analyst ratings
Consensus score 3.00 (1 = strong buy, 5 = sell) · mean target 7.50
- RBC CapitalSector Performmain2026-04-27
- BarclaysEqual-Weightmain2026-02-25
- Truist SecuritiesHoldmain2026-01-07
- BarclaysEqual-Weightinit2025-12-09
- RBC CapitalSector Performmain2025-05-02
- JefferiesHolddown2025-02-06
- RBC CapitalSector Performmain2025-01-30
- RBC CapitalSector Performmain2024-11-01
- RBC CapitalSector Performmain2024-08-02
- Piper SandlerUnderweightdown2024-08-02
Earnings
Next report: 2026-10-28
| Quarter | EPS actual | EPS estimate | Surprise |
|---|---|---|---|
| 3Q2025 | 1.16 | 1.06 | 0.11 |
| 4Q2025 | 1.10 | 1.26 | -0.16 |
| 1Q2026 | 0.78 | 0.69 | 0.09 |
| 2Q2026 | 1.26 | 1.01 | 0.25 |
SEC filings
- 10-QPeriodic Financial Reports2026-07-30Open
- 8-KCorporate Changes & Voting Matters2026-07-29Open
- 8-KCorporate Changes & Voting Matters2026-07-01Open
- SDSpecialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)2026-06-01Open
- 8-KCorporate Changes & Voting Matters2026-05-19Open
- 10-QPeriodic Financial Reports2026-04-30Open
- 8-KCorporate Changes & Voting Matters2026-04-29Open
- DEFA14AProxy Statements2026-04-08Open
- 8-KCorporate Changes & Voting Matters2026-03-02Open
- 10-KPeriodic Financial Reports2026-02-19Open
Latest BHC news
- Bausch Health Announces Availability of Solta Medical's Fraxel FTX® in Australia
Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC), a global, diversified pharmaceutical company, and its aesthetics business, Solta Medical, today announced the availability of Fraxel FTX® in Australia, expanding access to its latest skin resurfacing technology to Australian health care practitioners (HCPs) beginning September 1, 2026.
Tue, 01 Sep 2026 12:01:00 +0000
- Bausch Health's Ortho Dermatologics Announces the 2026 Aspire Higher Scholarship Winners
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and its dermatology business, Ortho Dermatologics, today announced the recipients of its 2026 Aspire Higher Scholarship Program. Since launching in 2013, the program has awarded 87 scholarships, totaling over $1 million, to students who have been treated for dermatologic conditions. This year, six inspiring students will each receive up to $10,000 to support their undergraduate or graduate studies.
Thu, 27 Aug 2026 12:02:00 +0000
- Bausch Health Announces 2026 Gastrointestinal Health Scholars Program Winners
Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today announced the recipients of its 2026 Salix Gastrointestinal Health Scholars Program. For the seventh year, Bausch Health is proud to award 10 deserving students living with a GI disease $10,000 each to further their higher education.
Mon, 17 Aug 2026 12:00:00 +0000
- Why Bausch Health Companies Stock Skyrocketed by Almost 40% Last Month
Much of this was due to a very well-received quarterly earnings report.
Mon, 10 Aug 2026 20:26:19 +0000
- Bausch Health CEO Thomas J. Appio Joins Bausch + Lomb Board
Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) ("Bausch Health" or the "Company"), today announced that its CEO, Thomas J. Appio, has been appointed to the board of directors of Bausch + Lomb Corporation (NYSE: BLCO)(TSX: BLCO), a subsidiary of Bausch Health Companies Inc., effective August 5, 2026.
Thu, 06 Aug 2026 11:04:00 +0000
- Can Bausch (BHC) Run Higher on Rising Earnings Estimates?
Bausch Health (BHC) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Fri, 21 Aug 2026 16:20:01 +0000
- Bausch (BHC) Upgraded to Buy: Here's What You Should Know
Bausch (BHC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Fri, 21 Aug 2026 16:00:06 +0000
- Bausch Health (BHC) Rockets 28% as Q2 Turnaround Fuels Recovery Outlook
Bausch Health (NYSE:BHC) climbed by 28.85 percent on Thursday to end at $6.03 apiece, after announcing a strong second quarter of the year that set the ground for the company’s profit recovery. In an updated report, the pharmaceutical giant said that it swung to a net income of $260 million during the period, marking a […]
Fri, 31 Jul 2026 04:03:32 +0000